Medical Devices Startups

IDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers. Its lead candidate, darovasertib, is in late-stage trials for uveal melanoma, with a pipeline spanning PKC inhibition, ADC+DDR combinations, the MTAP pathway, and KAT6/7 inhibition.

3 investors

Identical Implant develops dental implant technology. The company's specific products and target market are not described on this page excerpt.

3 investors

Idoven develops AI algorithms that analyze ECG data from wearable, mobile, and implantable devices to automatically identify cardiac patterns and arrhythmias at cardiologist-level accuracy. Its software is delivered to healthcare professionals via API and non-API tools, and includes predictive ECG-based models for assessing patient risk, such as the likelihood of developing atrial fibrillation.

3 investors

IDRx discovers, develops and delivers medicines and vaccines focused on cancer, HIV, respiratory diseases, and infectious diseases. The company aims to positively impact the health of 2.5 billion people by the end of the decade.

3 investors

iFAST Diagnostics develops a rapid antimicrobial susceptibility testing (AST) system that uses a microfluidic impedance chip to measure the electrical properties of individual bacteria, delivering resistant/susceptible and MIC results from Gram-negative blood cultures or bacterial isolates in under three hours. The technology is aimed at hospital clinical microbiology labs and clinicians to guide antibiotic prescribing and combat antimicrobial resistance, with a focus on the UK market.

3 investors

Immune Onc is a biotechnology company developing medicines to treat patients with hard-to-treat cancers and autoimmune diseases, with expertise in translational medicine and clinical development.

3 investors

ImmunoGenesis is a clinical-stage immuno-oncology biopharmaceutical company developing immune therapies for immune-excluded tumors, which resist standard PD-1 blockade. Its lead candidate, IMGS-001, is a cytotoxic immune checkpoint inhibitor aimed at cancers such as colorectal, ovarian, and non–small cell lung cancer.

3 investors

Immunophotonics is a clinical-stage biotech company developing novel treatments for solid-tumor cancers and infectious diseases by combining tumor ablation with systemic cancer immunotherapy. The company's intellectual property platform includes IP-001, designed to transform routine ablation procedures into systemically active cancer immunotherapy.

3 investors

Impel Pharmaceuticals develops therapies for patients using its drug delivery technology and expertise with small and large molecules. The company pursues partnerships, collaborations, and licensing opportunities to expand the therapeutic applications of its technology.

3 investors

Imperative Care develops medical technologies for treating stroke and other vascular diseases, aiming to address gaps across the patient care journey. The company focuses on devices and solutions for patients suffering from devastating vascular conditions.

3 investors

IMVARIA develops AI-driven software-as-medical-device solutions that analyze medical imaging and data to provide non-invasive diagnostic assessments for lung diseases, including idiopathic pulmonary fibrosis and interstitial lung disease. The company's FDA-authorized tools serve pulmonologists and other clinicians to reduce the need for invasive biopsy testing.

3 investors

INBRAIN Neuroelectronics develops graphene-based brain-computer therapeutics that combine neural signal decoding with AI to enable precision, adaptive treatments for neurological disorders. Founded in 2020, it works in the neurotech and medical device field, spanning neuroscience, semiconductors, AI, and clinical development.

3 investors

Incardatherapeutics develops drug therapies for treating atrial fibrillation using synergistic combinations of anti-arrhythmic agents, with delivery platforms designed for both hospital and at-home settings. The company targets reducing the clinical and economic burden of atrial fibrillation in the U.S. healthcare system.

3 investors

INDIGO Biosciences is a life sciences company led by professionals with expertise in life sciences, business management, and operations.

3 investors

InduPro develops next-generation protein therapeutics by leveraging inherent and induced proximity to modulate disease biology, with a focus on ADCs and T-cell engagers. The company built proprietary platforms — Membrane Interactomics (MInt) for target discovery, ARRIS for proximity modalities using multi-specific antibody technology, and internal antibody discovery and engineering — to identify targets and design therapeutic molecules.

3 investors

Online138 is an Indonesian platform offering World Cup-themed gaming experiences and a skills marketplace (SkillConnect) connecting users with local tutors, designers, tradespeople, and service providers. The platform emphasizes optimized performance across desktop and mobile devices.

3 investors

InoFab develops ultrasonic spirometers and cloud-based respiratory monitoring platforms for home and clinical use, enabling patients and healthcare providers to conduct and track lung function tests digitally.

3 investors

Inoviv provides custom multiplexed LC-MS proteomics panels for biomarker discovery and analysis in drug discovery and development. The company delivers pre-validated mass spectrometry workflows with end-to-end support for research and clinical applications.

3 investors

Insight-Med is a medtech company developing interventional cardiovascular devices, including a domestic fractional flow reserve (FFR) system approved by China's NMPA and an intravascular ultrasound (IVUS) system for precision diagnosis and treatment of cardiovascular diseases. It serves the interventional cardiology market with a portfolio spanning intravascular physiology and imaging, primarily in China.

3 investors

inSoma Bio develops biomaterial products for reconstruction plastic surgery, enabling surgeons to use patients' own tissue instead of synthetic implants and fillers for breast and facial reconstruction procedures.

3 investors

Inspire Medical Systems develops an FDA-approved implantable device that treats obstructive sleep apnea (OSA) by working with the patient's natural breathing, controlled via a small remote and intended for patients for whom CPAP is not effective. The device is surgically placed by an ENT and configured by a sleep medicine professional.

3 investors

Philips develops health technology and consumer products for patients, healthcare providers, and households, with an emphasis on durable, recyclable products. Its offerings span personal health and home devices as well as medical technologies for clinicians.

3 investors

Intellijoint Surgical is a Canadian medical technology company that develops surgical planning and navigation systems for total joint (hip and knee) replacement procedures. Its products, including the pre-operative planning tool Intellijoint VIEW, support orthopaedic surgeons in personalized alignment planning.

3 investors

InterVene, Inc. is a medical device company that has developed a fully integrated mechanical thrombectomy system to treat venous in-stent restenosis and residual thrombotic venous obstructions and occlusions. Its technology targets venous disease conditions such as postthrombotic syndrome that current therapies fail to address.

3 investors